-$0.10 Earnings Per Share Expected for BioScrip Inc (NASDAQ:BIOS) This Quarter

Wall Street analysts expect BioScrip Inc (NASDAQ:BIOS) to announce ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for BioScrip’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.12). BioScrip reported earnings per share of ($0.14) during the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The company is expected to announce its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that BioScrip will report full-year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next financial year, analysts forecast that the business will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.16) to ($0.14). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow BioScrip.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $178.96 million for the quarter, compared to the consensus estimate of $179.23 million. During the same period in the previous year, the business earned ($0.12) EPS. The firm’s revenue was up 6.2% compared to the same quarter last year.

Several research analysts recently weighed in on BIOS shares. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Thursday, June 20th. Canaccord Genuity reduced their price objective on shares of BioScrip from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Monday, March 18th. Barrington Research reissued a “buy” rating and set a $4.00 price objective on shares of BioScrip in a research note on Friday, May 3rd. TheStreet lowered shares of BioScrip from a “c-” rating to a “d” rating in a research note on Wednesday, April 3rd. Finally, Stephens lowered shares of BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target on the stock. in a research note on Monday, March 18th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $4.60.

BioScrip stock traded down $0.02 during midday trading on Wednesday, hitting $2.30. 14,757 shares of the stock were exchanged, compared to its average volume of 777,512. The firm has a fifty day moving average price of $2.12. BioScrip has a 52 week low of $1.56 and a 52 week high of $4.14. The stock has a market capitalization of $294.86 million, a PE ratio of -4.65 and a beta of 0.49.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Prescott Group Capital Management L.L.C. acquired a new stake in BioScrip during the 1st quarter valued at approximately $336,000. Rothschild & Co. Asset Management US Inc. boosted its holdings in shares of BioScrip by 68.1% during the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 3,812,471 shares of the company’s stock worth $7,625,000 after buying an additional 1,545,050 shares in the last quarter. Stephens Inc. AR bought a new position in shares of BioScrip during the 1st quarter worth approximately $405,000. Gamco Investors INC. ET AL boosted its holdings in shares of BioScrip by 2.4% during the 1st quarter. Gamco Investors INC. ET AL now owns 665,424 shares of the company’s stock worth $1,331,000 after buying an additional 15,500 shares in the last quarter. Finally, Roanoke Asset Management Corp NY boosted its holdings in shares of BioScrip by 10.7% during the 1st quarter. Roanoke Asset Management Corp NY now owns 463,780 shares of the company’s stock worth $928,000 after buying an additional 45,000 shares in the last quarter. 78.62% of the stock is currently owned by hedge funds and other institutional investors.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.